Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in High Risk, Stage IIB/IIC Cutaneous Melanoma
NCT07883759Phase 2Not yet recruiting
- Sponsor
- CHU de Besançon
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cutaneous melanoma (CM), sponsored by CHU de Besançon. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT07883759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883759.